Oral Cancer Drugs Deserve Parity
There have been some legislative efforts to bring parity to oral cancer drugs so that insurance companies treat them the same way as injectable cancer drugs.
The American Cancer Society takes a cautious approach to oral parity. Stephen Finan, senior director of policy for the American Cancer Society Cancer Action Network, said in an e-mail that the group is monitoring the issue "to better understand how health plans are handling coverage for both oral and injectable treatments -- specifically to make sure that affordability isn't challenged through increased premiums, stricter utilization management tools or exclusion of anti-cancer medications from formularies to contain costs."
Margaret Dick Tocknell is a reporter/editor with HealthLeaders Media.
- NCQA Releases Annual Health Plan Rankings
- Technology Lights Up Health Innovation Forum
- 3 NC Health Systems Form Shared Services Organization
- Hospital Pharmacies Prep for Drug Takebacks
- Few Winners Among MSSP Participants
- Interstate Medical Licensure Effort Advances
- Data Points to Boom in Private HIX
- Anthem Blue Cross, 7 CA Health Systems Create New Challenger, Business Model
- CMS Forecasts 4% Medicare Advantage Premium Hike in 2015
- How much does that x-ray cost? You can find out in NH